Neurologic diseases and neurogenetics
PRINCIPAL INVESTIGATORS
- Serge Jauma Classen
- Monica Povedano Panades
- Joan Prat Rojo
- Sergio Martínez Yélamos
- Jordi Gascon Bayarri
- Cristina Sanchez Castañeda
- Lucía Aja Rodríguez
- Matilde Calopa Garriga
- Pere Cardona Portela
- Merçè Falip Centellas
- Julia Miró Lladó
CLINICAL RESEARCHERS
- Sara Yagüe Jimeno
- Mariano Huerta Villanueva
- Laura Bau Vila
- Elisabet Matas Martín
- Pere Domènech Santasusana
- Misericordia Veciana De Las Heras
- Lucia Maria Romero Pinel
- Jaume Campdelacreu Fumado
- Dolors Dot Bach
- Isabel Fernández Conejero
- Elisabet Romero Gangonells
- Laura González Mera
- Maria Isabel Leon Moreno
- Raúl Domínguez Rubio
- Andres Julian Paipa Merchan
- Pablo Arroyo Pereiro
- Blanca Lara Rodríguez
- Velina Nedkova Hristova
POSTDOCTORAL RESEARCHERS
- Pol Andres Benito
PREDOCTORAL RESEARCHERS
- Silvia Muñoz Quiñones
- Albert Muñoz Vendrell
- Carla Marco Cazcarra
- Sergio Roca Pereira
- Roser Gomez Llopico
SCIENTIFIC SUPPORT
- Gisela Zamorano Garcia
- Sheila Álvarez Fornieles
- Abdelilah Assialioui Essanhaji
MANAGEMENT SUPPORT
- Susana Pobla Müller
- José Luis Moreno Morejón
- Cristina Terrafeta Pastor
Neuroscience
Neuroscience
Scientific production
51
PAPERS
Average IF: 11,169
17
LED PAPERS
Average IF: 4,456
14 PUBLICATIONS IN FIRST DECILE
29 PUBLICATIONS IN FIRST QUARTILE
32 PUBLICATIONS IN OPEN ACCESS
Selected publications
- Muñoz Vendrell,A;Campoy,S;Caronna,E;Alpuente,A;Torres Ferrus,M;Nieves Castellanos,C;Olivier,M et al, Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients., J. Headache Pain, 2023;24(1):63-63, doi:10.1186/s10194-023-01585-2
- Arroyo Pereiro,P;García Serrano,L;Morandeira,F;Urban,B;Mas,V;Framil,M;León,I et al, Kappa free light chains index in multiple sclerosis very long-term prognosis, Front. Immunol., 2023;141223514-1223514, doi:10.3389/fimmu.2023.1223514
- Van Daele,SH;Moisse,M;van Vugt,J;Zwamborn,R;van der Spek,R;van Rheenen,W;Van Eijk,K et al, Genetic variability in sporadic amyotrophic lateral sclerosis., Brain, 2023;00(9):1-10, doi:10.1093/brain/awad120
- Martakis,K;Claassen,J;Gascon Bayari,J;Goldschagg,N;Hahn,A;Hassan,A;Hennig,A et al, Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 Gangliosidoses, Neurology, 2023;100(10):1072-1083, doi:10.1212/WNL.0000000000201660
- Sarraj,A;Hassan,AE;Abraham,MG;Ortega Gutierrez,S;Kasner,SE;Hussain,MS;Chen,MC et al, Trial of Endovascular Thrombectomy for Large Ischemic Strokes, N. Engl. J. Med., 2023;388(14):1259-1271, doi:10.1056/NEJMoa2214403
Research highlights
PROJECTS
3 Granted competitive projects
2 Ongoing competitive projects
4 Started clinical trials
55 Ongoing clinical trials
8 Ongoing non competitive projects
INNOVATION
1 Patent
1 License
PUBLISHED WORKS
1 Clinical guideline
NETWORKS
TRICALS
RETICS- REEM
CSUR
XUEC
ENCALS
ERN
Selected projects
- MCI22004. Clinical trial to evaluate the administration of ApTOLL in ambulances and the neuroprotective effect in stroke patients. RACETOLL. Ministerio de Ciencia e Innovación. Budget: 487.992,8€. 2022-2025. PI: Cardona Portela, Pere.
- MCI23008. NexTOLL: A Phase IIb Clinical trial to the evaluate neuroprotective effect of ApTOLL in stroke patients. Ministerio de Ciencia e Innovación. Budget: 485.715,5€. 2023-2026. PI: Cardona Portela, Pere.
- INT23017. EPIDEMIOLOGICAL STUDY OF ALS IN COLOMBIA (SOUTH AMERICA) AND ETHIOPIA
(AFRICA). ALS Society of Canada ALS CAD. Budget: 65.802,5€. 2024-2025. PI: POVEDANO PANADES, MONICA. - HUB-NEU-2019-01. Ensayo clínico de eficacia y seguridad de efavirenz en pacientes diagnosticados de Niemann-Pick C del adulto con deterioro cognitivo : Eudra CT 2019-004498-18. Fundación Niemann-Pick España. Budget: 80.000€. 2022-2024. PI: Gascón Bayarri, Jordi.
- 21ACL033. ESTUDIO DE FASE III, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CON DOBLE ENMASCARAMIENTO Y DE GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD FENEBRUTINIB EN COMPARACIÓN CON TERIFLUNOMIDA EN PACIENTES ADULTOS ESCLEROSIS MÚLTIPLE RECURRENTE (EMR). Roche Farma, S.A. Budget: 112.560€. 2021- . PI: Martínez Yélamos, Sergio.